Publications

Differential Enhancement of Neutrophil Phagocytosis by Anti–Bactericidal/Permeability-Increasing Protein Antibodies
Theprungsirikul J, Skopelja-Gardner S, Wierzbicki RM, Sessions KJ, Rigby WFC. Differential Enhancement of Neutrophil Phagocytosis by Anti–Bactericidal/Permeability-Increasing Protein Antibodies. J Immunol. 2021. DOI: 10.4049/jimmunol.2100378

Killing three birds with one BPI: Bactericidal, opsonic, and anti-inflammatory functions.
Theprungsirikul J, Skopelja-Gardner S, Rigby WFC. Journal of Translational Autoimmunity. 2021. DOI: 10.1016/j.jtauto.2021.100105

Bactericidal/Permeability-Increasing Protein Preeminently Mediates Clearance of Pseudomonas aeruginosa In Vivo via CD18-Dependent Phagocytosis.
Theprungsirikul J, Skopelja-Gardner S, Burns AS, Wierzbicki RM, Rigby WFC
Front Immunol. 2021;12:659523. doi: 10.3389/fimmu.2021.659523. Epub 2021 Apr 26.
PMID: 33981306

Low-Avidity Autoantibodies against Bactericidal/Permeability-Increasing Protein Occur in Gram-Negative and Gram-Positive Bacteremia.
Theprungsirikul J, Thaden JT, Wierzbicki RM, Burns AS, Skopelja-Gardner S, Fowler VG Jr, Winthrop KL, Martin IW, Rigby WFC
Infect Immun. 2020 Sep 18;88(10) doi: 10.1128/IAI.00444-20. Epub 2020 Sep 18.
PMID: 32747603

Regulation of Pseudomonas aeruginosa-Mediated Neutrophil Extracellular Traps.
Skopelja-Gardner S, Theprungsirikul J, Lewis KA, Hammond JH, Carlson KM, Hazlett HF, Nymon A, Nguyen D, Berwin BL, Hogan DA, Rigby WFC
Front Immunol. 2019;10:1670. doi: 10.3389/fimmu.2019.01670. Epub 2019 Jul 18.
PMID: 31379861

Dissociation of systemic and mucosal autoimmunity in cystic fibrosis.
Theprungsirikul J, Skopelja-Gardner S, Meagher RE, Clancy JP, Zemanick ET, Ashare A, Rigby WFC
J Cyst Fibros. 2020 Mar;19(2):196-202. doi: 10.1016/j.jcf.2019.06.006. Epub 2019 Jun 28.
PMID: 31262645

Autoimmunity to bactericidal/permeability-increasing protein in bronchiectasis exhibits a requirement for Pseudomonas aeruginosa IgG response.
Skopelja-Gardner S, Theprungsirikul J, Meagher RE, Beliveau CM, Bradley KE, Avery M, Henkle E, Siegel S, Gifford AH, Winthrop KL, Rigby WFC
Eur Respir J. 2019 Feb;53(2) pii: 1801891. doi: 10.1183/13993003.01891-2018. Epub 2019 Feb 7.
PMID: 30385530

"NETtling" the host: Breaking of tolerance in chronic inflammation and chronic infection.
Skopelja-Gardner S, Jones JD, Rigby WFC
J Autoimmun. 2018 Mar;88:1-10. doi: 10.1016/j.jaut.2017.10.008.
PMID: 29100671

Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
Skopelja-Gardner S, Jones JD, Hamilton BJ, Danilov AV, Rigby WFC
J Immunol. 2017 Aug 15;199(4):1275-1282. doi: 10.4049/jimmunol.1602105. Epub 2017 Jul 14.
PMID: 28710251

The role for neutrophil extracellular traps in cystic fibrosis autoimmunity.
Skopelja S, Hamilton BJ, Jones JD, Yang ML, Mamula M, Ashare A, Gifford AH, Rigby WF
JCI Insight. 2016 Oct 20;1(17):e88912. doi: 10.1172/jci.insight.88912. Epub 2016 Oct 20.
PMID: 27777975

Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature.
Monaco WE, Jones JD, Rigby WF
Clin Rheumatol. 2016 Oct;35(10):2457-62. doi: 10.1007/s10067-016-3313-y. Epub 2016 May 21.
PMID: 27209045

Anti-carbamylated Protein Antibody Levels Correlate with Anti-Sa (Citrullinated Vimentin) Antibody Levels in Rheumatoid Arthritis.
Challener GJ, Jones JD, Pelzek AJ, Hamilton BJ, Boire G, de Brum-Fernandes AJ, Masetto A, Carrier N, Menard HA, Silverman GJ, Rigby WFC
J Rheumatol. 2016 Feb;43(2):273-281. doi: 10.3899/jrheum.150179. Epub 2015 Dec 15.
PMID: 26669911

Induction of interleukin-6 production by rituximab in human B cells.
Jones JD, Hamilton BJ, Skopelja S, Rigby WF
Arthritis Rheumatol. 2014 Nov;66(11):2938-46. doi: 10.1002/art.38798.
PMID: 25080282

Serum C-X-C motif chemokine 13 is elevated in early and established rheumatoid arthritis and correlates with rheumatoid factor levels.
Jones JD, Hamilton BJ, Challener GJ, de Brum-Fernandes AJ, Cossette P, Liang P, Masetto A, Menard HA, Carrier N, Boyle DL, Rosengren S, Boire G, Rigby WF
Arthritis Res Ther. 2014 Apr 25;16(2):R103. doi: 10.1186/ar4552. Epub 2014 Apr 25.
PMID: 24766912

Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program.
Emery P, Rigby W, Tak PP, Dorner T, Olech E, Martin C, Millar L, Travers H, Fisheleva E
PLoS One. 2014;9(2):e87379. doi: 10.1371/journal.pone.0087379. Epub 2014 Feb 3.
PMID: 24498318

Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study.
Rigby WF, Mease PJ, Olech E, Ashby M, Tole S
J Rheumatol. 2013 May;40(5):599-604. doi: 10.3899/jrheum.120924. Epub 2013 Apr 1.
PMID: 23547218

A rheumatoid factor paradox: inhibition of rituximab effector function.
Jones JD, Shyu I, Newkirk MM, Rigby WF
Arthritis Res Ther. 2013 Jan 25;15(1):R20. doi: 10.1186/ar4152. Epub 2013 Jan 25.
PMID: 23351360

Rituximab mediates loss of CD19 on B cells in the absence of cell death.
Jones JD, Hamilton BJ, Rigby WF
Arthritis Rheum. 2012 Oct;64(10):3111-8. doi: 10.1002/art.34560.
PMID: 22674374

Increased frequency of complement C4B deficiency in rheumatoid arthritis.
Rigby WF, Wu YL, Zan M, Zhou B, Rosengren S, Carlson C, Hilton W, Yu CY
Arthritis Rheum. 2012 May;64(5):1338-44. doi: 10.1002/art.33472.
PMID: 22076784

Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.
Rigby W, Ferraccioli G, Greenwald M, Zazueta-Montiel B, Fleischmann R, Wassenberg S, Ogale S, Armstrong G, Jahreis A, Burke L, Mela C, Chen A
Arthritis Care Res (Hoboken). 2011 May;63(5):711-20. doi: 10.1002/acr.20419.
PMID: 21557525